Clinical Trial Update: Post-Market Surveillance Study of ALK-Positive Advanced NSCLC Participants Treated With Iruplinalkib

View source ↗

Summary

Post-market surveillance clinical trial evaluating ALK-positive advanced non-small cell lung cancer patients treated with Iruplinalkib; the study is not yet rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alk-positive Non-small Cell Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Iruplinalkib (iruplinalkib)

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: NSCLC | Status: NOT_YET_RECRUITING